PILOT-STUDY AND RANDOMIZED TRIAL OF MITOXANTRONE AND IFOSFAMIDE FOR RELAPSED NON-HODGKINS-LYMPHOMA

被引：6

作者：

PRESCOTT, RJ ^{[1
]}

LEONARD, RCF ^{[1
]}

ALLAN, NC ^{[1
]}

ANGUS, B ^{[1
]}

BARRETT, A ^{[1
]}

DAS, SN ^{[1
]}

DAWSON, AA ^{[1
]}

HEPPLESTON, A ^{[1
]}

LESSELLS, AM ^{[1
]}

LUCIE, NP ^{[1
]}

LUCRAFT, HH ^{[1
]}

MACKIE, MJ ^{[1
]}

MACLAREN, KS ^{[1
]}

MATHESON, LM ^{[1
]}

PARKER, AC ^{[1
]}

PROCTOR, SJ ^{[1
]}

SARKAR, TK ^{[1
]}

SOUKOP, M ^{[1
]}

STEWARD, WP ^{[1
]}

WHITE, JM ^{[1
]}

机构：

[1] UNIV EDINBURGH,SCH MED,SCOTTISH CANC TRIALS OFF,TEVIOT PL,EDINBURGH EM8 9AG,SCOTLAND

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 1-2期

关键词：

PILOT STUDY; RANDOMIZED TRIAL; MITOXANTRONE; IFOSFAMIDE; RELAPSE; NON-HODGKINS LYMPHOMA;

D O I：

10.3109/10428199309054737

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This report compares a pilot study followed by a trial of the combination of mitozantrone and ifosfamide for relapsed lymphoma. In the pilot study (15 patients) toxicity and activity of the combination was tested on a variety of relapsed non-Hodgkin's lymphoma. In the trial (19 patients) the therapy was confined to patients with high and intermediate grade non-Hodgkin's lymphoma in which the combination was compared against single agent mitozantrone. The median survival of patients on the pilot and trial was very poor at around six months, but some individuals survived for several years from both groups. The main toxicities of treatment were, predictably, nausea and vomiting and bone marrow suppression on the combination, and bone marrow suppression alone on the single agent mitozantrone. There was no obvious disadvantage of the single agent treatment when compared with the combination, but this statement has to be interpreted with caution given the high death rate amongst all patients and the very small numbers who entered the randomised trial.

引用

页码：111 / 114

页数：4

共 50 条

[31] TROFOSFAMIDE IN NON-HODGKINS-LYMPHOMA - A PHASE-II STUDY [J].

WIST, E ;

RISBERG, T .

ACTA ONCOLOGICA, 1991, 30 (07) :819-821

[32] PROLONGED DISEASE-FREE SURVIVAL IN PEDIATRIC NON-HODGKINS-LYMPHOMA USING IFOSFAMIDE-CONTAINING COMBINATION CHEMOTHERAPY [J].

GADELMAWLA, N ;

HAMZA, MR ;

ABDELHADI, S ;

ELTANNIR, O ;

HUSSEIN, MH ;

ELHADDAD, A ;

ADDE, M ;

MAGRATH, I .

HEMATOLOGICAL ONCOLOGY, 1991, 9 (4-5) :281-286

[33] THE RELATIONSHIP BETWEEN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA [J].

HARRIS, NL .

SEMINARS IN DIAGNOSTIC PATHOLOGY, 1992, 9 (04) :304-310

[34] High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin’s lymphoma [J].

Igor Aurer ;

Damir Nemet ;

Zdravko Mitrović ;

Dino Dujmović ;

Sandra Bašić-Kinda ;

Ivo Radman ;

Dubravka Sertić ;

Fedor Šantek ;

Marko Kralik ;

Snježana Dotlić ;

Sanja Mazić ;

Boris Labar .

Annals of Hematology, 2016, 95 :1129-1136

[35] High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma [J].

Aurer, Igor ;

Nemet, Damir ;

Mitrovic, Zdravko ;

Dujmovic, Dino ;

Basic-Kinda, Sandra ;

Radman, Ivo ;

Sertic, Dubravka ;

Santek, Fedor ;

Kralik, Marko ;

Dotlic, Snjezana ;

Mazic, Sanja ;

Labar, Boris .

ANNALS OF HEMATOLOGY, 2016, 95 (07) :1129-1136

[36] A CASE OF NON-HODGKINS-LYMPHOMA ASSOCIATED WITH HYPERCALCEMIA [J].

SUEMARU, S ;

KAGEYAMA, J ;

OTA, Z ;

OHNOSHI, T ;

SAKAMOTO, K ;

KAMURA, J .

ACTA MEDICA OKAYAMA, 1991, 45 (01) :55-59

[37] P53 AND NON-HODGKINS-LYMPHOMA [J].

SYMMANS, WF ;

KATZ, RL .

DIAGNOSTIC ONCOLOGY, 1994, 4 (01) :22-25

[38] CYTODIAGNOSIS OF A PRIMARY NON-HODGKINS-LYMPHOMA OF BONE [J].

ASCOLI, V ;

FACCIOLO, F ;

NARDI, F .

DIAGNOSTIC CYTOPATHOLOGY, 1994, 11 (02) :168-173

[39] IMAGE-ANALYSIS IN NON-HODGKINS-LYMPHOMA [J].

STEVENS, MW ;

LEONG, ASY .

JOURNAL OF HISTOTECHNOLOGY, 1992, 15 (03) :263-276

[40] PRIMARY NON-HODGKINS-LYMPHOMA OF THE TEMPORAL BONE [J].

BOCKMUHL, U ;

BRUCHHAGE, KL ;

ENZMANN, H .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1995, 252 (06) :376-378

← 1 2 3 4 5 →